Alison M Schram (Alison Schram)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 20

Top Topics

Tyrosine Kinase

Top Venues

Nature medicine

Cancer discovery

Clinical cancer research : an official journal of the American Association for Cancer Research

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Claire F Friedman, Beryl L Manning-Geist, Qin Zhou, Tara Soumerai, Aliya Holland, Arnaud Da Cruz Paula, Hunter Green, Melih Arda Ozsoy, Alexia Iasonos, Travis Hollmann, Mario M Leitao, Jennifer J Mueller, Vicky Makker, William P Tew, Roisin E O'Cearbhaill, Ying L Liu, Maria M Rubinstein, Tiffany Troso-Sandoval, Stuart M Lichtman, Alison M Schram, Chrisann Kyi, Rachel N Grisham, Pamela Causa Andrieu, E John Wherry, Carol Aghajanian, Jorge S Reis-Filho, Martee L Hensley, Dmitriy Zamarin
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Nature medicine 30 (5) (2024)
Claire F Friedman, Beryl L Manning-Geist, Qin Zhou, Tara Soumerai, Aliya Holland, Arnaud Da Cruz Paula, Hunter Green, Melih Arda Ozsoy, Alexia Iasonos, Travis Hollmann, Mario M Leitao, Jennifer J Mueller, Vicky Makker, William P Tew, Roisin E O'Cearbhaill, Ying L Liu, Maria M Rubinstein, Tiffany Troso-Sandoval, Stuart M Lichtman, Alison M Schram, Chrisann Kyi, Rachel N Grisham, Pamela Causa Andrieu, E John Wherry, Carol Aghajanian, Jorge S Reis-Filho, Martee L Hensley, Dmitriy Zamarin
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Nature medicine 30 (5) (2024)
Dedipya Bhamidipati, Alison M Schram
Emerging Tumor-Agnostic Molecular Targets. Molecular cancer therapeutics (2024)
Claire F Friedman, Beryl L Manning-Geist, Qin Zhou, Tara Soumerai, Aliya Holland, Arnaud Da Cruz Paula, Hunter Green, Melih Arda Ozsoy, Alexia Iasonos, Travis Hollmann, Mario M Leitao, Jennifer J Mueller, Vicky Makker, William P Tew, Roisin E O'Cearbhaill, Ying L Liu, Maria M Rubinstein, Tiffany Troso-Sandoval, Stuart M Lichtman, Alison M Schram, Chrisann Kyi, Rachel N Grisham, Pamela Causa Andrieu, E John Wherry, Carol Aghajanian, Jorge S Reis-Filho, Martee L Hensley, Dmitriy Zamarin
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Nature medicine 30 (5) (2024)
Claire F Friedman, Beryl L Manning-Geist, Qin Zhou, Tara Soumerai, Aliya Holland, Arnaud Da Cruz Paula, Hunter Green, Melih Arda Ozsoy, Alexia Iasonos, Travis Hollmann, Mario M Leitao, Jennifer J Mueller, Vicky Makker, William P Tew, Roisin E O'Cearbhaill, Ying L Liu, Maria M Rubinstein, Tiffany Troso-Sandoval, Stuart M Lichtman, Alison M Schram, Chrisann Kyi, Rachel N Grisham, Pamela Causa Andrieu, E John Wherry, Carol Aghajanian, Jorge S Reis-Filho, Martee L Hensley, Dmitriy Zamarin
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Nature medicine (2024)
Claire F Friedman, Beryl L Manning-Geist, Qin Zhou, Tara Soumerai, Aliya Holland, Arnaud Da Cruz Paula, Hunter Green, Melih Arda Ozsoy, Alexia Iasonos, Travis Hollmann, Mario M Leitao, Jennifer J Mueller, Vicky Makker, William P Tew, Roisin E O'Cearbhaill, Ying L Liu, Maria M Rubinstein, Tiffany Troso-Sandoval, Stuart M Lichtman, Alison M Schram, Chrisann Kyi, Rachel N Grisham, Pamela Causa Andrieu, E John Wherry, Carol Aghajanian, Jorge S Reis-Filho, Martee L Hensley, Dmitriy Zamarin
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Nature medicine 30 (5) (2024)
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B Barry Toure, Songping Zhao, Roberto Valverde, Patrick J O'Hearn, Demetri T Moustakas, Heike Schonherr, Nastaran Gerami-Moayed, Alexander M Taylor, Brandi M Hudson, Damian J Houde, Debjani Pal, Lindsey Foster, Hakan Gunaydin, Pelin Ayaz, Dina A Sharon, Lipika Goyal, Alison M Schram, Suneel D Kamath, Cori Ann Sherwin, Oleg Schmidt-Kittler, Kai Yu Jen, Fabien Ricard, Beni B Wolf, David E Shaw, Donald A Bergstrom, James Watters, Jessica B Casaletto
RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations. Cancer discovery (2023)
Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce, Alessandro A Boezio, Lucian DiPietro, Adam Frost, Fabrizio Giordanetto, Erika Paige Hamilton, Katherine Harris, Michael J Holliday, Tamieka L Hunter, Amanda Iskandar, Yongli Ji, Alexandre Larivée, Jonathan R LaRochelle, Andre Lescarbeau, Fabien Llambi, Brenda Lormil, Mary M Mader, Brenton G Mar, Iain Martin, Thomas H McLean, Klaus Michelsen, Yakov Pechersky, Erika G Puente, Ramin Samadani, Alison M Schram, Kelley Shortsleeves, Sweta Swaminathan, Shahein Tajmir, Gege Tan, Yong Tang, Roberto Valverde, Bryan Wehrenberg, Jeremy Wilbur, Bret R Williams, Hongtao Zeng, W Patrick Walters, Beni B Wolf, David E Shaw, Donald A Bergstrom, James Watters, Brian K Shoichet, Pascal D Fortin, D Randal Kipp
Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer discovery (2023)
Lisa Werr, Dennis Plenker, Marcel A Dammert, Carina Lorenz, Johannes Brägelmann, Hannah L Tumbrink, Sebastian Klein, Anna Schmitt, Reinhard Büttner, Thorsten Persigehl, Kevan M Shokat, F Thomas Wunderlich, Alison M Schram, Martin Peifer, Martin L Sos, Hans Christian Reinhardt, Roman K Thomas
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. Molecular cancer therapeutics 21 (5) (2022)
Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N Gorelick, Matthew T Chang, Debyani Chakravarty, Elena I Gavrila, Mark T A Donoghue, JianJong Gao, Swati Patel, Sizhi Paul Gao, Margaret H Reynolds, Sarah M Phillips, Tara Soumerai, Wassim Abida, David M Hyman, Alison M Schram, David B Solit, Lillian M Smyth, Barry S Taylor
AKT mutant allele-specific activation dictates pharmacologic sensitivities. Nature communications 13 (1) (2022)
Alison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J Sisso, Marissa S Mattar, Allan J W Lui, Morana Vojnic, Sara H Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford, Marie N O'Connor, Cecile A W Geuijen, Ron C J Schackmann, Jeroen J Lammerts van Bueren, Ernesto Wasserman, Elisa De Stanchina, Eileen M O'Reilly, Marc Ladanyi, Alexander E Drilon, Romel Somwar
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer discovery 12 (5) (2022)
Yonina R Murciano-Goroff, Alison M Schram, Ezra Y Rosen, Helen Won, Yixiao Gong, Anne Marie Noronha, Yelena Y Janjigian, Zsofia K Stadler, Jason C Chang, Soo-Ryum Yang, Diana L Mandelker, Kenneth Offit, Michael F Berger, Mark T A Donoghue, Chaitanya Bandlamudi, Alexander E Drilon
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies. Nature communications 13 (1) (2022)
Michael Herman Chui, Jason C Chang, Yanming Zhang, Ahmet Zehir, Alison M Schram, Jason A Konner, Alexander E Drilon, Arnaud Da Cruz Paula, Jorge S Reis-Filho, Rachel N Grisham
Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma. JCO precision oncology 5 (2021)
Jason C Chang, Michael D Offin, Christina J Falcon, David N Brown, Brian R Loomis, Fanli Meng, Vasilisa A Rudneva, Helen H Won, Sharon Amir, Joseph Montecalvo, Patrice Desmeules, Kyuichi Kadota, Prasad S Adusumilli, Valerie W Rusch, Sarah Teed, Joshua K Sabari, Ryma Benayed, Khedoudja Nafa, Laetitia Borsu, Bob T Li, Alison M Schram, Maria E Arcila, William D Travis, Marc Ladanyi, Alexander E Drilon, Natasha Rekhtman
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (14) (2021)
Alexander E Drilon, Michael Duruisseaux, Ji-Youn Han, Masaoki Ito, Christina J Falcon, Soo-Ryum Yang, Yonina R Murciano-Goroff, Haiquan Chen, Morihito Okada, Miguel Ángel Molina-Vila, Marie Wislez, Philippe Brun, Clarisse Dupont, Eva Branden, Giulio Rossi, Alexa B Schrock, Siraj M Ali, Valérie Gounant, Fanny Magne, Torsten Gerriet Blum, Alison M Schram, Isabelle Monnet, Jin-Yuan Shih, Joshua K Sabari, Maurice Pérol, Viola W Zhu, Misako Nagasaka, Robert Doebele, D Ross Camidge, Maria Arcila, Sai-Hong Ignatius Ou, Denis Moro-Sibilot, Rafael Rosell, Lucia Anna Muscarella, Stephen V Liu, Jacques Cadranel
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (25) (2021)
Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M Schram, Helen H Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Amaia Arruabarrena-Aristorena, Srushti Kittane, Fan Wu, Yanyan Cai, Sabrina Arena, Benedetta Mussolin, Neil Vasan, Alexander N Gorelick, Michael F Berger, Ofra Novoplansky, Sankar Jagadeeshan, Yi Liao, Uwe Rix, Sandra Misale, Barry S Taylor, Alberto Bardelli, Jaclyn F Hechtman, David M Hyman, Moshe Elkabets, Elisa de Stanchina, Chandra S Verma, Andrea Ventura, Alexander E Drilon, Maurizio Scaltriti
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer discovery 11 (1) (2020)
Lillian M Smyth, Sarina A Piha-Paul, Helen H Won, Alison M Schram, Cristina Saura, Sherene Loi, Janice Lu, Geoffrey I Shapiro, Dejan Juric, Ingrid A Mayer, Carlos L Arteaga, Macarena I de la Fuente, Adam M Brufksy, Iben Spanggaard, Morten Mau Sorensen, Monica Arnedos, Victor Moreno, Valentina Boni, Joohyuk Sohn, Lee S Schwartzberg, Xavier Gonzalez, Andres Cervantes, François-Clement Bidard, Alexander N Gorelick, Richard B Lanman, Rebecca J Nagy, Gary A Ulaner, Sarat Chandarlapaty, Komal Jhaveri, Elena I Gavrila, Catherine Zimel, S Duygu Selcuklu, Myra Melcer, Aliaksandra Samoila, Yanyan Cai, Maurizio Scaltriti, Grace Mann, Feng Xu, Lisa D Eli, Melanie Dujka, Alshad S Lalani, Richard Bryce, José Baselga, Barry S Taylor, David B Solit, Funda Meric-Bernstam, David M Hyman
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer discovery 10 (2) (2019)
Ryma Benayed, Michael D Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan N Ptashkin, Helen Won, Jason Chang, Darragh Halpenny, Alison M Schram, Charles M Rudin, David M Hyman, Maria E Arcila, Michael F Berger, Ahmet Zehir, Mark G Kris, Alexander E Drilon, Marc Ladanyi
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (15) (2019)
Ezra Y Rosen, Debra A Goldman, Jaclyn F Hechtman, Ryma Benayed, Alison M Schram, Emiliano Cocco, Sophie Shifman, Yixiao Gong, Ritika Kundra, James P Solomon, Alberto Bardelli, Maurizio Scaltriti, Alexander E Drilon, Alexia Iasonos, Barry S Taylor, David M Hyman
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (7) (2019)
Emiliano Cocco, Jamal Benhamida, Sumit Middha, Ahmet Zehir, Kerry Mullaney, Jinru Shia, Rona Yaeger, Zarina Yelskaya, Donna Wong, Liliana Villafania, Khedoudja Nafa, Maurizio Scaltriti, Alexander E Drilon, Leonard B Saltz, Alison M Schram, Zsofia K Stadler, David M Hyman, Ryma Benayed, Marc Ladanyi, Jaclyn F Hechtman
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer research 79 (6) (2019)